VEA
ARQT icon

Virtus ETF Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

Virtus ETF Advisers’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,606
Closed -$163K – 466
2025
Q2 		$163K Hold
11,606
– – 0.1% 229
2025
Q1 		$182K Buy
11,606
+5,803
+100% +$81.8K 0.12% 225
2024
Q4 		$80.8K Sell
5,803
-4,064
-41% -$44.5K 0.03% 342
2024
Q3 		$91.8K Buy
9,867
+175
+2% +$1.73K 0.04% 389
2024
Q2 		$90.1K Buy
+9,692
New +$87.6K 0.04% 356
2023
Q4 		– Sell
-9,248
Closed -$49.1K – 432
2023
Q3 		$49.1K Sell
9,248
-924
-9% -$7.86K 0.03% 415
2023
Q2 		$96.9K Buy
10,172
+4,084
+67% +$45.3K 0.06% 397
2023
Q1 		$67K Sell
6,088
-2,335
-28% -$33.8K 0.04% 407
2022
Q4 		$125K Buy
8,423
+3,148
+60% +$55K 0.07% 407
2022
Q3 		$101K Buy
5,275
+43
+0.8% +$974 0.04% 420
2022
Q2 		$111K Sell
5,232
-5,127
-49% -$105K 0.04% 403
2022
Q1 		$200K Sell
10,359
-606
-6% -$10.3K 0.09% 198
2021
Q4 		$227K Buy
10,965
+3,661
+50% +$72.9K 0.09% 194
2021
Q3 		$174K Sell
7,304
-388
-5% -$8.85K 0.08% 302
2021
Q2 		$210K Sell
7,692
-2,610
-25% -$73.5K 0.09% 310
2021
Q1 		$298K Buy
10,302
+185
+2% +$5.78K 0.13% 241
2020
Q4 		$285K Sell
10,117
-1,964
-16% -$48.1K 0.12% 234
2020
Q3 		$354K Sell
12,081
-1,637
-12% -$43.7K 0.19% 185
2020
Q2 		$415K Buy
+13,718
New +$396K 0.2% 185

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus ETF Advisers's ARQT Position: Q3 2025 in Review

Virtus ETF Advisers sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 11,606 shares — an estimated $163K sold.

Virtus ETF Advisers first reported a position in ARQT in Q2 2020 and held it in 19 quarters. The position peaked at $415K in Q2 2020. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Virtus ETF Advisers reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,606 Arcutis Biotherapeutics shares in Q3 2025, an estimated $163K.
  • Virtus ETF Advisers first reported a position in Arcutis Biotherapeutics in Q2 2020 and held it in 19 quarters.
  • Virtus ETF Advisers's Arcutis Biotherapeutics position peaked at $415K in Q2 2020.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Virtus ETF Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.